Bettina Fishman
Research Subjects
Research Interests
Bettina Fishman has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Asaph Zaretsky
Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
1 shared publication - Atara Novak
Bonus BioGroup Ltd, Matam Advanced Technology Park, 31905, Haifa, Israel
1 shared publication - Avinoam Kadouri
Bonus BioGroup Ltd, Matam Advanced Technology Park, 31905, Haifa, Israel
1 shared publication - Dror Ben-David
Bonus BioGroup Ltd, Matam Advanced Technology Park, 31905, Haifa, Israel.
1 shared publication - Ephraim Tzur
Department of Oral and Maxillofacial Surgery, Assaf Harofeh Medical Center, Zerifin, Israel
1 shared publication - Guy Rubin
Emek Medical Center
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-11
Autologous cell-coated particles for the treatment of segmental bone defects—a new cell therapy approach
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are one of the most potent adult stem cells, capable of differentiating into bone, cartilage, adipose, muscle, and others. An innovative autologous AT-MSC-derived cell-based product (BonoFill-II) for bone tissue regeneration was developed to be suited as a bone graft for segmental bone defects. BonoFill-II was transplanted into 8 sheep with 3.2-cm full cortex segmental defect formed in the tibia. Bone regeneration was followed by X-ray radiographs for 12 weeks. At experiment termination, the healed tibia bones were analyzed by computed tomography, histology, and mechanical tests. Our results indicate that one dose of BonoFill-II injectable formula led to an extensive bone growth within the transplantation site and to a complete closure of the critical gap in the sheep’s tibia in a relatively short time (8–12 weeks), with no inflammation and no other signs of graft rejection. This new and innovative product opens new prospects for the treatment of long bone defects. Injection of BonoFill-II (an innovative autologous cell therapy product for bone tissue regeneration) into a critical size segmental defect model (3.2 cm), generated in the sheep tibia, achieved full bridging of the gap in an extremely short period (8–12 weeks).
- 1 July 2019
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 14 (1) , 1-11
Open AccessAutologous cell-coated particles for the treatment of segmental bone defects—a new cell therapy approach
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are one of the most potent adult stem cells, capable of differentiating into bone, cartilage, adipose, muscle, and others. An innovative autologous AT-MSC-derived cell-based product (BonoFill-II) for bone tissue regeneration was developed to be suited as a bone graft for segmental bone defects. BonoFill-II was transplanted into 8 sheep with 3.2-cm full cortex segmental defect formed in the tibia. Bone regeneration was followed by X-ray radiographs for 12 weeks. At experiment termination, the healed tibia bones were analyzed by computed tomography, histology, and mechanical tests. Our results indicate that one dose of BonoFill-II injectable formula led to an extensive bone growth within the transplantation site and to a complete closure of the critical gap in the sheep’s tibia in a relatively short time (8–12 weeks), with no inflammation and no other signs of graft rejection. This new and innovative product opens new prospects for the treatment of long bone defects. Injection of BonoFill-II (an innovative autologous cell therapy product for bone tissue regeneration) into a critical size segmental defect model (3.2 cm), generated in the sheep tibia, achieved full bridging of the gap in an extremely short period (8–12 weeks).